– USA, CA – VMDOC a leading SMART Patient Care Management Platform provider, announced today that it has appointed serial entrepreneur, Kia Mousavi, as chief executive office and a member of the board of directors, effective immediately. The appointment is part of the company’s planned growth strategy and expansion to new markets.
Dr. Shahram Gholami, co-founder and Chief Medical Officer of VMDOC commented: “Kia brings to the team his experience in software industry and expertise in software sales along with his passion for the modernization and improvement in healthcare. He is a great addition to the team and we are excited to have him take the lead.”
“Kia is a great fit with our leadership team. He brings with him the strategic agility, business acumen, vision, and mission-driven orientation. We are delighted that he has accepted the position with strong determination to take VMDOC to the next level,” said Alvin Vo, co-founder and the CTO of VMDOC.
Mr. Mousavi brings with him over 20 years of software industry experience in large complex enterprise and commercial products and services in various verticals. In addition to providing technical and business leadership services to industry giants such as Adobe, IBM, SIEMENS, Publicis and Alcatel-Lucent, he has co-founded Protecode, a leading Software Composition Analysis Platform, which was acquired by Synopsys in 2015.
VMDOC provides patients an active voice in their wellness and treatment plan and the opportunity to receive the highest quality of care through its SMART (Secure, Measurable, Automated and Real-Time) Comprehensive Patient Care Management Platform, VMDOC empowers providers and patients alike to meet high-value care objectives in wellness, chronic, and acute disease management.
For more information : http://www.vmdoc.com
- Disclaimer - News, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.